Deals And M NEWS
- Argos between 'roca'-nd hard place as phase III mRCC trial halted for futility
- Keep on Truxima: Celltrion wins EU nod for biosimilar, other submissions nearing
- Retail investors cash in on Neovacs $69M lupus pact in China
- Potential drug target found for Chikungunya virus arthritis
- Takeda lands Japan rights for cabozantinib in Ex...
- Beijing's Apollobio to bring Inovio's new HPV drug to China marketplace
- Chi-Med's savolitinib hits phase II endpoints in Met-driven PRCC
- Samsung's biosimilars come to fruition despite scandals, company says
- Germline gene editing should be allowed – in certain situations
- Tivantinib misses OS endpoint in phase III liver...
Cast Your Vote
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.